The ARG tyrosine kinase is inhibited by STI571.

被引：0
|
作者：
Okuda, K
Weisberg, E
Gilliland, DG
Griffin, JD
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1487
引用
收藏
页码：344A / 344A
页数：1
相关论文
共 50 条
  • [21] Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
    Mol, CD
    Dougan, DR
    Schneider, TR
    Skene, RJ
    Kraus, ML
    Scheibe, DN
    Snell, GP
    Zou, H
    Sang, BC
    Wilson, KP
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (30) : 31655 - 31663
  • [22] Characterization of Bcr-Abl-positive cell lines with inherent and acquired resistance to STI571.
    Scappini, B
    Gatto, SR
    Kantarjian, HM
    Onida, F
    Keating, MJ
    Beran, M
    BLOOD, 2001, 98 (11) : 182B - 182B
  • [23] Constitutive Activation of C-kit by the Juxtamembrane but Not the Catalytic Domain Mutations Is Inhibited Selectively by Tyrosine Kinase Inhibitors STI571 and AG1296
    Shuji Ueda
    Hirokazu Ikeda
    Masao Mizuki
    Jun Ishiko
    Itaru Matsumura
    Hirokazu Tanaka
    Hirohiko Shibayama
    Hiroyuki Sugahara
    Emi Takai
    Xian Zhang
    Takashi Machii
    Yuzuru Kanakura
    International Journal of Hematology, 2002, 76 : 427 - 435
  • [24] Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296
    Ueda, S
    Ikeda, H
    Mizuki, M
    Ishiko, J
    Matsumura, I
    Tanaka, H
    Shibayama, H
    Sugahara, H
    Takai, E
    Zhang, X
    Machii, T
    Kanakura, Y
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (05) : 427 - 435
  • [25] Dose respose effect and time to clinical response in patients with interferon refractory CML treated with STI571.
    Mauro, MJ
    Druker, BJ
    Braziel, RM
    Launder, TM
    Ford, J
    O'Dwyer, ME
    BLOOD, 2000, 96 (11) : 735A - 735A
  • [26] The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
    Podtcheko, A
    Ohtsuru, A
    Tsuda, S
    Namba, H
    Saenko, V
    Nakashima, M
    Mitsutake, N
    Kanda, S
    Kurebayashi, J
    Yamashita, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04): : 1889 - 1896
  • [27] Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
    Joensuu, H
    Roberts, PJ
    Sarlomo-Rikala, M
    Andersson, LC
    Tervahartiala, P
    Tuveson, D
    Silberman, SL
    Capdeville, R
    Dimitrijevic, S
    Druker, B
    Demetri, GD
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1052 - 1056
  • [28] Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor
    Calvo, E
    Fernández, FJ
    Forteza, J
    Brugarolas, A
    MEDICINA CLINICA, 2002, 119 (10): : 396 - 397
  • [29] STI571: A tyrosine kinase inhibitor for the treatment of CML - Validating the promise of molecularly targeted therapy
    Druker, BJ
    FASEB JOURNAL, 2002, 16 (04): : A134 - A134
  • [30] c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571)
    Nagar, Bhushan
    JOURNAL OF NUTRITION, 2007, 137 (06): : 1518S - 1523S
12345